Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 10/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 9/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 9/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 9/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237835 | 0.89 | PDE1C (0.65) | CACNA1BADORA3ADRA1ACACNA1CCACNA1F | |
| SCHEMBL8298086 | 0.88 | CACNA1C (0.71) | CACNA1BADORA3CACNA1CCACNA1FCACNA1D | |
| SCHEMBL9264367 | 0.88 | CACNA1C (0.71) | CACNA1BADORA3CACNA1CCACNA1FCACNA1D | |
| SCHEMBL8301606 | 0.88 | CACNA1C (0.71) | CACNA1BADORA3CACNA1CCACNA1FCACNA1D | |
| SCHEMBL8298083 | 0.88 | CACNA1C (0.71) | CACNA1BADORA3CACNA1CCACNA1FCACNA1D | |
| SCHEMBL27516111 | 0.88 | ADRA1A (0.58) | CACNA1BADORA3ADRA1ACACNA1CCACNA1F | |
| SCHEMBL5854523 | 0.87 | CACNA1B (0.80) | CACNA1BADORA3ADRA1ACACNA1CCACNA1F | |
| SCHEMBL5854519 | 0.87 | CACNA1B (0.80) | CACNA1BADORA3ADRA1ACACNA1CCACNA1F | |
| SCHEMBL7239516 | 0.86 | CACNA1B (0.49) | CACNA1BADORA3ADRA1ACACNA1CCACNA1F | |
| SCHEMBL9263384 | 0.84 | CACNA1B (0.64) | CACNA1BADORA3ADRA1ACACNA1CCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6310076-B1 | TREATING BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, TREATING DISEASES MEDIATED BY ALPHA-1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-6211198-B1 | BENIGN PROSTATE HYPERPLASIA; INTRAOCULAR PRESSURE; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | CACNA1B 272/4885ADORA3 2012/4885ADRA1A 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.